Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION363 in FUS-associated amyotrophic lateral sclerosis
NL-OMON54223Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ulefnersen in amyotrophic lateral sclerosis (ALS) and amyotrophic lateral sclerosis (fALS) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Joint rank analysis of functional impairment and survival, In-clinic ALSFRS-R total score and 2 more. Started Oct 2022; status: recruiting.
02
Drugs
ulefnersen
03
Conditions
amyotrophic lateral sclerosis (ALS)amyotrophic lateral sclerosis (fALS)
Beyond the preview
Go deeper on NL-OMON54223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54223.